compare glp 1 drugs GLP-1 Options | Ozempic v Mounjaro | WeightWatchers GLP-1 Agonists for Weight Loss:

Description

Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.

A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)

To support our research and testing, we may earn a commission if you sign up or purchase through certain links on this page at no additional cost to you